Where Regulatory Leaders Converge
Master Europe's Regulations: Adapt faster. Innovate smarter. Win bigger.
Transform regulatory complexity into competitive advantage with expert insights and tailored strategies that accelerate approvals, optimise regulatory compliance and unlock incentives for growth.
The Regulatory Strategy program at BIO-Europe
Regulatory leadership redefined: Strategy. Collaboration. Business impact.
BIO-Europe's brand new regulatory strategy program brings together thought leaders to help you craft a winning regulatory strategy to set you up for success.
This is where the conversations that fuel growth happen - showcasing innovative ways to navigate complex regulatory pathways, reduce time-to-market, and position yourself for global competitiveness.
Join us in Europe and define how your strategy will change the world.
Navigate Regulatory Transformation
- Gain insights into the General Pharmaceutical Legislation (GPL) EU Biotech Act, ATMP, and SoHO regulations and their impact on your business
- Maximize incentives and market exclusivity in the GPL for regulatory data protection and SPCs
- Dissect how to utilize regulatory sandboxes for innovation
- Learn how to adapt to new EU regulations like the EU MDR and IVDR, AI Act, HTA Regulations and the European Health Data Space (EHDS)
Accelerating Innovation in Biotech
- Explore pathways for Cell & Gene therapies under the EU Biotech Act and the FDA and MHRA Rare Therapies Launch Pad
- Learn about regulatory processes under EMA and FDA principles for AI’s transformation in drug discovery and clinical trials
- Understand the role of Real World Evidence (RWE) and DARWIN-EU in shaping future approvals
- Strategies to position biotech innovations for global competitiveness and seize opportunities in evolving markets
Regulatory Incentives and Market Access
- Navigating new HTA regulations and rare disease economic models
- How to align with investor expectations by leveraging regulatory incentives and addressing approval delays
- Discover funding opportunities under the EU Innovation Act and maximize market exclusivity through SPCs and other incentives
- Overcome barriers to commercialization by comparing global regulatory frameworks and aligning with global standards
Beyond Regulatory — Explore and unlock the full BIO-Europe experience
- Connect with 8,000+ biotech leaders and explore the macro forces defining the industry's next chapter
- Understand how rising R&D pressures and external innovation are transforming regulatory frameworks and relationships in the biotech and pharma industry
- Explore the role of AI in reshaping regulatory strategies, policy alignment, and decision-making for biotech innovation
- Learn how evolving investment strategies and productivity shifts influence regulatory priorities and future frameworks
Bold voices. Executive-level insights. Meet your BIO-Europe regulatory leaders.
At BIO-Europe 2026, we're dedicating premium space at one of the industry's most renowned industry events - and we've assembled the absolute best to lead it. You'll gain unparalleled access to insights that typically stay behind closed doors, learning directly from those who set the standards and turn challenges into competitive advantages. These are the voices defining the regulatory landscape... and now, you have a seat at the table.
Who should attend? Your regulatory community is at BIO-Europe
Senior leadership executives, global leaders, and decision-makers responsible for regulatory strategy at mid-size biotech and large pharma, from early development to established commercial operations - there is a seat for you at BIO-Europe 2026
• Chief Executive Officer (CEO)
• Chief Scientific Officer (CSO)
• Chief Medical Officer (CMO)
• General Counsel
• Scientific Policy
• Regulatory Affairs
• Regulatory Operations
• Global Regulatory Affairs
• Global Regulatory Operations
• Regulatory Policy
• Regulatory Intelligence
How will you attend?
FAQs
Why is BIO-Europe introducing a Regulatory Strategy track?
In a rapidly evolving regulatory landscape, biotech and pharmaceutical companies face critical challenges that demand strategic foresight and adaptability. With shifting policies, emerging technologies, and heightened expectations for innovation, regulatory leaders must navigate complexity, seize opportunities, and future-proof their strategies to help their company’s stay competitive. This conference is your chance to tackle the big questions, gain actionable insights, and position your organization for success in Europe’s dynamic regulatory environment.
How does Regulatory Strategy align with BIO-Europe's partnering focus?
Whether you're seeking licensing agreements, co-development opportunities, or investor backing, your regulatory strategy influences how partners evaluate risk, scalability, and long-term value. This track positions regulatory affairs as a strategic enabler of partnerships - not an afterthought - helping attendees make informed decisions that strengthen deal attractiveness and partnership outcomes.
Who should attend the Regulatory Strategy track?
This program is tailored for professionals driving regulatory strategies across both pharmaceutical and biotech organizations, from early-stage start-ups to established enterprises. Whether you're shaping policy, executing strategies, or navigating complex regulatory landscapes, this program delivers actionable insights to accelerate growth and regulatory compliance.
Key Job Titles:
- Vice Presidents, Executive Directors, Directors, Heads, and Managers in:
- Regulatory Affairs
- Regulatory Operations
- Global Regulatory Affairs
- Regulatory Policy
- Regulatory Intelligence
- Scientific Policy
- Regulatory Data
What makes this different from other regulatory conferences?
Key Focus Areas:
- Understanding the Current Landscape: What are the latest developments in European regulations, and how can you align your strategy to avoid missteps and maximize incentives?
- Adapting to Change: How can you evolve your regulatory approach to meet the demands of new frameworks like the GPL, Biotech Act, AI Act, and HTAR?
- Driving Innovation: What practical steps can you take to leverage regulatory sandboxes, AI-driven technologies, and tailored pathways for orphan and unmet medical need products?
- Strategic Agility: Is your regulatory strategy dynamic enough to respond to policy shifts, emerging trends, and competitive pressures?
Why Attend?
- Unlock Opportunities: Discover how to leverage new incentives and frameworks to accelerate innovation and market access.
- Stay Ahead of the Curve: Gain insights into the latest regulatory updates and learn how to adapt to Europe’s evolving pharmaceutical landscape.
- Collaborate and Innovate: Exchange ideas with industry leaders and regulatory experts to refine your strategies and gain fresh perspectives.
- Future-Proof Your Strategy: Equip yourself with the tools and knowledge to navigate complexity, mitigate risks, and drive long-term success.
This conference is more than just a discussion. It's a platform to help you recalibrate your regulatory strategy, harness innovation, and stay agile in a dynamic environment. Whether it’s mastering new frameworks, addressing unmet needs, or preparing for the future, you’ll leave with actionable insights to keep your organization competitive, compliant, and ready for what’s next.
What topics will the Regulatory Strategy program cover?
With contributions from industry leaders and regulator, this event is your opportunity to stay ahead of regulatory changes, maximize incentives, and drive innovation in Europe’s competitive pharmaceutical and biotech sectors.
Driving Innovation Regulatory Excellence: Align Regulatory Processes with Investment and Innovation Goals
- Unlocking incentives under GPL and the Biotech Act to accelerate innovation and exclusivity
- Advancing orphan, paediatric, and unmet medical needs with tailored pathways and breakthrough definitions
- Leveraging regulatory sandboxes and AI to transform drug development and novel therapeutics
- Navigating GDPR, EHDS, and AI Act compliance to harness clinical research data and global transparency
- Understand the implications of HTA regulations on the dynamics of market access
- Examine EU MDR, and IVDR revisions while integrating AI-driven advancements
Key sessions include:
- Accelerating innovation and market exclusivity through regulatory incentives
- Examining the enhanced incentives under updated GPL regulations: implications for orphan and pediatric medicine
- Crafting your regulatory strategy to align with GPL implementation
- Harnessing regulatory sandboxes to drive innovation in novel therapeutics & technologies
- Mastering the shifting regulatory landscape: leveraging the Biotech Act for innovation and global success